Abstract
Molecular imaging is a fast growing field in biomedical research. The discovery, development and continual improvement of molecular probes are important for ongoing research efforts in molecular imaging. Human serum albumin (HSA) offers favorable charac-teristics and opportunities as a platform protein for molecular imaging probe discovery and optimization. It has many advantages, includ-ing alternation of biodistribution and pharmacokinetic properties of molecular imaging probes, enhancing the blood half-life of bio-molecules, and making these molecules multivalent, all of which make HSA a promising carrier for cancer-targeted imaging and therapy. Numerous studies have focused on the development and application of HSA-based cancer imaging and treatment. This review gives a brief account of albumin-based molecular probes, focusing on their applications in cancer molecular imaging, such as PET/SPECT, MRI and optical imaging.
Keywords: Human serum albumin (HSA), molecular imaging, PET, optical imaging, cancer, biodistribution, molecular imaging probes, cancer-targeted imaging, positron emission tomography (PET), single photon emission tomography (SPECT)
Current Pharmaceutical Design
Title: Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Volume: 18 Issue: 8
Author(s): Meng Yang, Susan Hoppmann, Luxi Chen and Zhen Cheng
Affiliation:
Keywords: Human serum albumin (HSA), molecular imaging, PET, optical imaging, cancer, biodistribution, molecular imaging probes, cancer-targeted imaging, positron emission tomography (PET), single photon emission tomography (SPECT)
Abstract: Molecular imaging is a fast growing field in biomedical research. The discovery, development and continual improvement of molecular probes are important for ongoing research efforts in molecular imaging. Human serum albumin (HSA) offers favorable charac-teristics and opportunities as a platform protein for molecular imaging probe discovery and optimization. It has many advantages, includ-ing alternation of biodistribution and pharmacokinetic properties of molecular imaging probes, enhancing the blood half-life of bio-molecules, and making these molecules multivalent, all of which make HSA a promising carrier for cancer-targeted imaging and therapy. Numerous studies have focused on the development and application of HSA-based cancer imaging and treatment. This review gives a brief account of albumin-based molecular probes, focusing on their applications in cancer molecular imaging, such as PET/SPECT, MRI and optical imaging.
Export Options
About this article
Cite this article as:
Yang Meng, Hoppmann Susan, Chen Luxi and Cheng Zhen, Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315830
DOI https://dx.doi.org/10.2174/138161212799315830 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
An Insight into Drug Repositioning for the Development of Novel Anti-Cancer Drugs
Current Topics in Medicinal Chemistry Curcuminoid Metabolism and its Contribution to the Pharmacological Effects
Current Drug Metabolism Recent Patents on Biomarkers in Oral Cancers
Recent Patents on Biomarkers Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Editorial A New Year of Excellence
Current Molecular Medicine Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Anticancer Therapeutic Strategies Based on CDK Inhibitors
Current Pharmaceutical Design A Rationale for the Use of Proton Pump Inhibitors as Antineoplastic Agents
Current Pharmaceutical Design WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening Insulin-Like Growth Factor 2 - The Oncogene and its Accomplices
Current Pharmaceutical Design Recent Patents in Circulating Cell-Free Tumor DNA as Biomarker in Cancer
Recent Patents on Biomarkers The Use of Ghrelin and Ghrelin Receptor Agonists as a Treatment for Animal Models of Disease: Efficacy and Mechanism
Current Pharmaceutical Design Malignant Pleural Mesothelioma in 2011. Is there a Gold Standard Therapy?
Current Respiratory Medicine Reviews Regulation of EMT by KLF4 in Gastrointestinal Cancer
Current Cancer Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Potent Chemopreventive Agents Against Pancreatic Cancer
Current Cancer Drug Targets